Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Analysis and Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report Overview
In the 7MM, there were 62,543,523 prevalent cases of chronic obstructive pulmonary disease (COPD) in 2023. The prevalent cases of COPD will register an AGR of more than 1% during 2023-2033. Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, debilitating, and progressive disease characterized by persistent respiratory symptoms and airflow limitation. It is a common lung disorder in the aging population with systemic features ensuring morbidity and mortality in all stages of severity. Consequently, COPD represents a significant healthcare concern with increased prevalence and mortality rates globally. With approximately 3 million deaths every year being attributed to COPD, the disease is the third leading cause of mortality worldwide.
COPD Market Outlook, 2023-2033 (Prevalent Cases)
Buy the Full Report for More Insights into the COPD Market Forecast
The chronic obstructive pulmonary disease (COPD)market research report provides an overview of the risk factors, comorbidities, and global and historical trends for COPD in the 7 major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report also includes a 10-year epidemiological forecast for the prevalent cases of COPD and the five-year diagnosed prevalent cases of COPD.
| Market Size (2023) | 62,543,523 Cases |
| AGR (2023-2033) | >1% |
| Forecast Period | 2023-2033 |
| Key Countries | · The US
· The UK · France · Japan · Germany · Spain · Italy |
| Key Sex Segments | · Men
· Women |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
COPD Market Segmentation by Country
The key countries in COPD market across the 7MM are the US, France, Germany, Spain, Italy, the UK, and Japan. In 2023, the US accounted for the highest number of prevalent cases of COPD in the 7MM.
COPD Market Analysis by Country, 2023 (%)
Buy the Full Report for More Country Insights into the COPD Market
Download a Free Report Sample
COPD Market Segmentation by Sex
Based on sex, the market can be segmented into men and women. In 2023, the number of diagnosed prevalent cases of COPD was higher in women than in men in the 7MM. Among the 7MM, Japan had the largest difference in the diagnosed prevalent cases of COPD between men and women.
COPD Market Analysis by Sex, 2023 (%)
Buy the Full Report for More Sex Insights into the COPD Market
Segments Covered in the Report
COPD Epidemiology Country Outlook
- The US
- France
- Germany
- Spain
- Italy
- The UK
- Japan
COPD Epidemiology Sex Outlook
- Men
- Women
Scope
- This report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- The report includes a 10-year epidemiology forecast for the total prevalent cases and diagnosed prevalent cases of COPD. The total prevalent cases and the diagnosed prevalent cases of COPD are segmented by age (35–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) and sex.
- The report also includes the diagnosed prevalent cases of COPD by severity classification by GOLD 2016 criteria using the Modified Medical Research Council (mMRC) questionnaire scores and/or the COPD Assessment Test (CAT) scores, as well as the diagnosed prevalent cases of COPD by severity classification by GOLD 2023 criteria using mMRC and/or CAT scores.
- Although not covered in this report, the diagnosed prevalent cases of COPD with asthma-COPD overlap syndrome (ACOS) by GOLD 2016 or updated GOLD criteria can be found in the model.
- This epidemiology forecast for COPD is supported by data obtained from peer-reviewed articles and population-based studies. GlobalData epidemiologists applied the GOLD staging system to diagnose and classify COPD patients across the 7MM.
- Accordingly, the total prevalent cases and diagnosed prevalent cases of COPD in the 7MM are based on the latest data available by GOLD criteria.
- The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the forecast total prevalent cases and the diagnosed prevalent cases of COPD across these markets.
Reasons to Buy
The Chronic obstructive pulmonary disease (COPD) epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global COPD market.
- Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for COPD therapeutics in each of the markets covered.
Table of Contents
Table
Figures
Frequently asked questions
-
How many prevalent cases of COPD were seen in the 7MM in 2023?
In 2023, there were 62,543,523 prevalent cases of COPD in the 7MM.
-
What will the growth rate of the COPD market be during the forecast period?
The prevalent cases of COPD will register an AGR of more than 1% during 2023-2033.
-
Which was the leading sex segment in the COPD market in 2023?
In 2023, the number of diagnosed prevalent cases of COPD was higher in women in the 7MM.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Chronic Obstructive Pulmonary Disease (COPD) reports


